2017 Q3 Form 10-Q Financial Statement
#000114420417059130 Filed on November 14, 2017
Income Statement
| Concept | 2017 Q3 | 2016 Q3 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $1.080M | $990.0K |
| YoY Change | 9.09% | 5.32% |
| % of Gross Profit | ||
| Research & Development | $1.452M | $1.452M |
| YoY Change | -0.02% | 13.26% |
| % of Gross Profit | ||
| Depreciation & Amortization | $166.2K | $163.3K |
| YoY Change | 1.78% | 1.04% |
| % of Gross Profit | ||
| Operating Expenses | $2.230M | $2.440M |
| YoY Change | -8.61% | 90.35% |
| Operating Profit | -$2.230M | -$2.440M |
| YoY Change | -8.61% | |
| Interest Expense | $125.0K | $245.0K |
| YoY Change | -48.98% | 0.0% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $224.9K | -$621.0K |
| YoY Change | -136.21% | -167.64% |
| Pretax Income | -$2.006M | -$3.060M |
| YoY Change | -34.46% | 134.13% |
| Income Tax | $0.00 | $0.00 |
| % Of Pretax Income | ||
| Net Earnings | -$2.006M | -$3.061M |
| YoY Change | -34.49% | 134.24% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | -$0.03 | -$0.05 |
| Diluted Earnings Per Share | -$0.03 | -$0.05 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 63.31M shares | 58.18M shares |
| Diluted Shares Outstanding | 63.31M shares | 58.18M shares |
Balance Sheet
| Concept | 2017 Q3 | 2016 Q3 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $13.51M | $21.91M |
| YoY Change | -38.34% | -25.68% |
| Cash & Equivalents | $13.51M | $21.91M |
| Short-Term Investments | ||
| Other Short-Term Assets | $190.0K | $210.0K |
| YoY Change | -9.52% | 31.25% |
| Inventory | ||
| Prepaid Expenses | $207.6K | |
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $13.70M | $22.12M |
| YoY Change | -38.07% | -25.38% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $11.14M | $11.62M |
| YoY Change | -4.15% | -4.23% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | $381.1K | $389.4K |
| YoY Change | -2.12% | -2.08% |
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $40.00K | $90.00K |
| YoY Change | -55.56% | -25.0% |
| Total Long-Term Assets | $11.57M | $12.10M |
| YoY Change | -4.42% | -4.39% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $13.70M | $22.12M |
| Total Long-Term Assets | $11.57M | $12.10M |
| Total Assets | $25.27M | $34.22M |
| YoY Change | -26.17% | -19.1% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $910.0K | $930.0K |
| YoY Change | -2.15% | 16.25% |
| Accrued Expenses | $34.19K | $35.65K |
| YoY Change | -4.09% | 81.93% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $4.200M | $5.690M |
| YoY Change | -26.19% | |
| Long-Term Debt Due | $5.689M | |
| YoY Change | ||
| Total Short-Term Liabilities | $5.284M | $6.939M |
| YoY Change | -23.85% | 605.82% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $3.320M |
| YoY Change | -100.0% | -55.79% |
| Other Long-Term Liabilities | $1.460M | $3.740M |
| YoY Change | -60.96% | 21.04% |
| Total Long-Term Liabilities | $1.460M | $7.059M |
| YoY Change | -79.32% | -33.44% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $5.284M | $6.939M |
| Total Long-Term Liabilities | $1.460M | $7.059M |
| Total Liabilities | $6.747M | $14.00M |
| YoY Change | -51.8% | 20.8% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$77.13M | -$67.89M |
| YoY Change | 13.62% | |
| Common Stock | $58.20K | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $18.52M | $20.23M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $25.27M | $34.22M |
| YoY Change | -26.17% | -19.09% |
Cashflow Statement
| Concept | 2017 Q3 | 2016 Q3 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$2.006M | -$3.061M |
| YoY Change | -34.49% | 134.24% |
| Depreciation, Depletion And Amortization | $166.2K | $163.3K |
| YoY Change | 1.78% | 1.04% |
| Cash From Operating Activities | -$1.557M | -$2.225M |
| YoY Change | -30.03% | 34.84% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $30.43K | $24.44K |
| YoY Change | 24.55% | -92.68% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | -$30.00K | -$20.00K |
| YoY Change | 50.0% | -93.94% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | ||
| YoY Change | ||
| NET CHANGE | ||
| Cash From Operating Activities | -$1.557M | -$2.225M |
| Cash From Investing Activities | -30.00K | -20.00K |
| Cash From Financing Activities | ||
| Net Change In Cash | -$1.557M | -$2.225M |
| YoY Change | -30.03% | 12.36% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$1.557M | -$2.225M |
| Capital Expenditures | $30.43K | $24.44K |
| Free Cash Flow | -$1.587M | -$2.249M |
| YoY Change | -29.43% | 13.39% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.03 | |
| CY2016Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.05 | |
| CY2017Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.03 | |
| CY2016Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.05 | |
| CY2017Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
34004 | USD |
| CY2017Q3 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
818783 | USD |
| CY2017Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2017Q3 | us-gaap |
Accounts Payable Trade Current
AccountsPayableTradeCurrent
|
90359 | USD |
| CY2016Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2017Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
95382979 | USD |
| CY2017Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
2230446 | USD |
| CY2016Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
2440449 | USD |
| CY2017Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2230446 | USD |
| CY2016Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2440449 | USD |
| CY2017Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
24394 | USD |
| CY2016Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
14176 | USD |
| CY2017Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-2005555 | USD |
| CY2017Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2005555 | USD |
| CY2016Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3061444 | USD |
| CY2017Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
63305 | USD |
| CY2017Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-75128691 | USD |
| CY2017Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
20321942 | USD |
| CY2017Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
27002814 | USD |
| CY2017Q2 | us-gaap |
Liabilities
Liabilities
|
6680872 | USD |
| CY2017Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
34192 | USD |
| CY2017Q3 | us-gaap |
Liabilities
Liabilities
|
6746557 | USD |
| CY2017Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-77134246 | USD |
| CY2017Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
18519209 | USD |
| CY2017Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
25265766 | USD |
| CY2017Q3 | us-gaap |
Security Deposit
SecurityDeposit
|
3515 | USD |
| CY2017Q3 | us-gaap |
Other Assets
OtherAssets
|
44672 | USD |
| CY2017Q2 | us-gaap |
Security Deposit
SecurityDeposit
|
3515 | USD |
| CY2017Q2 | us-gaap |
Other Assets
OtherAssets
|
58929 | USD |
| CY2017Q2 | nnvc |
Service Agreements
ServiceAgreements
|
55414 | USD |
| CY2017Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
125000 | USD |
| CY2017Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1155228 | USD |
| CY2017Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
13776561 | USD |
| CY2017Q2 | us-gaap |
Assets Current
AssetsCurrent
|
15289627 | USD |
| CY2017Q2 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
166667 | USD |
| CY2017Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
15099461 | USD |
| CY2017Q2 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
340695 | USD |
| CY2017Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4665518 | USD |
| CY2017Q2 | us-gaap |
Assets
Assets
|
27002814 | USD |
| CY2017Q3 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
381130 | USD |
| CY2017Q2 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
383198 | USD |
| CY2016Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1452137 | USD |
| CY2017Q3 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
458954 | USD |
| CY2017Q2 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
458954 | USD |
| CY2017Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
11271060 | USD |
| CY2017Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1075218 | USD |
| CY2017Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2505501 | USD |
| CY2017Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
13806994 | USD |
| CY2017Q3 | nnvc |
Service Agreements
ServiceAgreements
|
41157 | USD |
| CY2017Q3 | us-gaap |
Assets
Assets
|
25265766 | USD |
| CY2017Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2671690 | USD |
| CY2017Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
13512240 | USD |
| CY2017Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
5283932 | USD |
| CY2016Q3 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
13291 | USD |
| CY2016Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
58179949 | shares |
| CY2017Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
63307083 | shares |
| CY2017Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
63307083 | shares |
| CY2016Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
58179949 | shares |
| CY2017Q3 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
564848 | USD |
| CY2017Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
224891 | USD |
| CY2016Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-620995 | USD |
| CY2016Q3 | nnvc |
Discount On Convertible Debentures
DiscountOnConvertibleDebentures
|
403462 | USD |
| CY2017Q3 | us-gaap |
Interest Expense
InterestExpense
|
125000 | USD |
| CY2016Q3 | us-gaap |
Interest Expense
InterestExpense
|
245000 | USD |
| CY2017Q3 | nnvc |
Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued
SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued
|
158799 | USD |
| CY2017Q3 | nnvc |
Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One
StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne
|
27000 | USD |
| CY2017Q3 | nnvc |
Stock Issued For Payment Of Director Fees Value
StockIssuedForPaymentOfDirectorFeesValue
|
11250 | USD |
| CY2017Q3 | nnvc |
Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services
StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices
|
5773 | USD |
| CY2016Q3 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
38250 | USD |
| CY2017Q3 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
38250 | USD |
| CY2016Q3 | us-gaap |
Depreciation
Depreciation
|
163286 | USD |
| CY2017Q3 | us-gaap |
Depreciation
Depreciation
|
166189 | USD |
| CY2016Q3 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
2067 | USD |
| CY2017Q3 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
2068 | USD |
| CY2016Q3 | nnvc |
Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
|
13291 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-11895 | USD |
| CY2016Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2224823 | USD |
| CY2017Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1556788 | USD |
| CY2016Q3 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-2249258 | USD |
| CY2017Q3 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-1587221 | USD |
| CY2016Q3 | us-gaap |
Interest Paid Net
InterestPaidNet
|
286667 | USD |
| CY2017Q3 | us-gaap |
Interest Paid Net
InterestPaidNet
|
166667 | USD |
| CY2016Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
21912927 | USD |
| CY2017Q3 | nnvc |
Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
|
564848 | USD |
| CY2017Q3 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
2254 | USD |
| CY2016Q3 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
17148 | USD |
| CY2017Q3 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
5773 | USD |
| CY2016Q3 | nnvc |
Preferred Shares Issued As Compensation
PreferredSharesIssuedAsCompensation
|
182898 | USD |
| CY2017Q3 | nnvc |
Preferred Shares Issued As Compensation
PreferredSharesIssuedAsCompensation
|
158799 | USD |
| CY2017Q3 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-14257 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-8678 | USD |
| CY2017Q3 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-45427 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
172864 | USD |
| CY2017Q3 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
478088 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
-109015 | USD |
| CY2017Q3 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
188 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
47 | USD |
| CY2017Q3 | us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
-41667 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
-41668 | USD |
| CY2017Q3 | dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2000-07-25 | |
| CY2017Q3 | us-gaap |
Business Acquisition Date Of Acquisition Agreement1
BusinessAcquisitionDateOfAcquisitionAgreement1
|
2005-05-12 | |
| CY2016Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6633848 | shares |
| CY2017Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6685292 | shares |
| CY2017Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.03 | |
| CY2016Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.05 | |
| CY2017Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-2005555 | USD |
| CY2016Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-3061444 | USD |
| CY2017Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
63307083 | shares |
| CY2016Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
58179949 | shares |
| CY2017Q2 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
7996402 | USD |
| CY2017Q3 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
7996402 | USD |
| CY2017Q2 | nnvc |
Office Equipment Gross
OfficeEquipmentGross
|
48486 | USD |
| CY2017Q3 | nnvc |
Office Equipment Gross
OfficeEquipmentGross
|
48486 | USD |
| CY2017Q2 | us-gaap |
Furniture And Fixtures Gross
FurnitureAndFixturesGross
|
5607 | USD |
| CY2017Q3 | us-gaap |
Furniture And Fixtures Gross
FurnitureAndFixturesGross
|
5607 | USD |
| CY2017Q2 | us-gaap |
Fixtures And Equipment Gross
FixturesAndEquipmentGross
|
5466066 | USD |
| CY2017Q3 | us-gaap |
Fixtures And Equipment Gross
FixturesAndEquipmentGross
|
5496499 | USD |
| CY2017Q3 | us-gaap |
Land
Land
|
260000 | USD |
| CY2017Q2 | us-gaap |
Land
Land
|
260000 | USD |
| CY2017Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
383198 | USD |
| CY2017Q3 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
381130 | USD |
| CY2013Q3 | nnvc |
Warrants Issued
WarrantsIssued
|
2945428 | shares |
| CY2014Q1 | nnvc |
Warrants Issued
WarrantsIssued
|
2479935 | shares |
| CY2013Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
2810071 | shares |
| CY2014Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
2479935 | shares |
| CY2017Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2017Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2017Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
| CY2017Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
| CY2017Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
63335194 | shares |
| CY2017Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
63335194 | shares |
| CY2017Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
63306774 | shares |
| CY2017Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
63306774 | shares |
| CY2017Q3 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note 1 - Organization and Nature of Business</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> NanoViricides, Inc. (the “Company”) was incorporated under the laws of the State of Colorado on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">July 25, 2000</font> as <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Edot-com.com, Inc<b>.</b></font> which was organized for the purpose of conducting internet retail sales. On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation. On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 12, 2005</font>, the corporations were merged and Edot-com.com, Inc<b>.,</b> the Nevada corporation, became the surviving entity.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired NanoViricides, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”). NanoViricides, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80,000,000</font> newly issued shares of ECMM common stock resulting in an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000,000</font> shares of ECMM common stock issued and outstanding. NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000</font> shares of the Company’s Common Stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">As a result of the Exchange transaction, the former NVI stockholders held approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of ECMM by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">   </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. Under the License Agreements, TheraCour Pharma will receive a royalty upon sale of resulting products from NanoViricides. There is no royalty payable to date.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On February 15, 2010 the Company executed an Additional License Agreement with TheraCour.  Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 shares <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(adjusted for the 3.5 to 1 reverse split)</font> of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  The Series A Preferred Stock is convertible, only in the event of a “change of control” of the Company, as defined in the designation of Series A Preferred Stock (see Note 2 for further details), into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Series A Preferred Stock do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the Holder’s approval. The <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares were valued at the par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font>.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2017Q3 | us-gaap |
Business Acquisition Name Of Acquired Entity
BusinessAcquisitionNameOfAcquiredEntity
|
Edot-com.com, Inc. | |
| CY2017Q3 | us-gaap |
Debt Instrument Redemption Description
DebtInstrumentRedemptionDescription
|
the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of common stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of common stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of common stock (the Redemption Warrants, and collectively with (i) (iv), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act. | |
| CY2017Q3 | us-gaap |
Related Party Transaction Description Of Transaction
RelatedPartyTransactionDescriptionOfTransaction
|
charge its costs (direct and indirect) plus no more than 30% of direct costs | |
| CY2017Q3 | us-gaap |
Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
|
2000 | USD |
| CY2017Q3 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
25227 | USD |
